Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis [0.03%]
卫生系统实施药物基因组临床决策支持的费用效益分析研究
Shangqing Jiang,Patrick C Mathias,Nathaniel Hendrix et al.
Shangqing Jiang et al.
We constructed a cost-effectiveness model to assess the clinical and economic value of a CDS alert program that provides pharmacogenomic (PGx) testing results, compared to no alert program in acute coronary syndrome (ACS) and atrial fibrill...
Combining familial hypercholesterolemia and statin genetic studies as a strategy for the implementation of pharmacogenomics. A multidisciplinary approach [0.03%]
结合家族性高胆固醇血症和他汀类药物的遗传学研究作为实施药物基因组学的战略。一种多学科的方法
Luis Ramudo-Cela,Sara Santana-Martínez,Maite García-Ramos et al.
Luis Ramudo-Cela et al.
The diagnostic process of familial hypercholesterolemia frequently involves the use of genetic studies. Patients are treated with lipid-lowering drugs, frequently statins. Although pharmacogenomic clinical practice guidelines focusing on ge...
Opportunities for personalizing colorectal cancer care: an analysis of SEER-medicare data [0.03%]
基于SEER-Medicare数据的结直肠癌个性化治疗机会分析研究
Zachary T Rivers,Helen M Parsons,Pamala A Jacobson et al.
Zachary T Rivers et al.
United States clinical practice guidelines for metastatic colorectal cancer recommend use of medications impacted by genetic variants but do not recommend testing. We analyzed real-world treatment using a cancer registry and claims dataset ...
Correction to: Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review [0.03%]
多病共存或服用多种药物患者的药理遗传学干预以改善预后的系统评价的订正
Joseph O&#x;Shea,Mark Ledwidge,Joseph Gallagher et al.
Joseph O&#x;Shea et al.
Published Erratum
The pharmacogenomics journal. 2022 Mar;22(2):146. DOI:10.1038/s41397-022-00273-9 2022
A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges [0.03%]
发展中国家药物基因组学的成本效益的系统综述：实施挑战
Asif Sukri,Mohd Zaki Salleh,Collen Masimirembwa et al.
Asif Sukri et al.
The major challenges that delay the implementation of pharmacogenomics based clinical practice in the developing countries, primarily the low- and middle-income countries need to be recognized. This review was conducted to systematically re...
Implementation of CYP2D6 copy-number imputation panel and frequency of key pharmacogenetic variants in Finnish individuals with a psychotic disorder [0.03%]
在芬兰精神病患者中实现CYP2D6拷贝数内插板以及关键药物基因组变异频率的评估研究
Katja Häkkinen,Johanna I Kiiski,Markku Lähteenvuo et al.
Katja Häkkinen et al.
We demonstrate that CYP2D6 copy-number variation (CNV) can be imputed using existing imputation algorithms. Additionally, we report frequencies of key pharmacogenetic variants in individuals with a psychotic disorder from the genetically bo...
Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review [0.03%]
多病共存或联用多种药物患者的用药基因组学干预以改善预后的系统评价
Joseph O&#x;Shea,Mark Ledwidge,Joseph Gallagher et al.
Joseph O&#x;Shea et al.
Conventional medicines optimisation interventions in people with multimorbidity and polypharmacy are complex and yet limited; a more holistic and integrated approach to healthcare delivery is required. Pharmacogenetics has potential as a co...
HLA-B*07:02 and HLA-C*07:02 are associated with trimethoprim-sulfamethoxazole respiratory failure [0.03%]
HLA-B*07:02和HLA-C*07:02与磺胺甲基异噁唑所致的呼吸衰竭相关
Jennifer L Goldman,Jenna O Miller,Neil Miller et al.
Jennifer L Goldman et al.
We have identified an underrecognized severe adverse drug reaction (ADR) of trimethoprim-sulfamethoxazole (TMP-SMX) associated respiratory failure in previously healthy children and young adults. We investigated potential genetic risk facto...
UGT1A1 genetic variants are associated with increases in bilirubin levels in rheumatoid arthritis patients treated with sarilumab [0.03%]
UGT1A1基因变异与类风湿关节炎患者使用萨利鲁马布治疗后胆红素水平升高有关
Nan Lin,Amy Damask,Anita Boyapati et al.
Nan Lin et al.
Sarilumab is a human monoclonal antibody against interleukin (IL)-6Rα that has been approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) and an inadequate response or intolerance to one ...
Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota [0.03%]
在明尼苏达州东南部的一组白人非西班牙裔人群中识别对阿片类镇痛药反应的性别特异性遗传关联
Guilherme S Lopes,Jaime L Lopes,Suzette J Bielinski et al.
Guilherme S Lopes et al.
The study of sex-specific genetic associations with opioid response may improve the understanding of inter-individual variability in pain treatments. We investigated sex-specific associations between genetic variation and opioid response. W...